Trials / Recruiting
RecruitingNCT06490328
Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer
A Phase 3, Multi-center, Single-group, Open-label Study to Evaluate the Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 154 (estimated)
- Sponsor
- Dongkook Pharmaceutical Co., Ltd. · Industry
- Sex
- Male
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
A phase 3, multi-center, single-group, open-label study to evaluate the efficacy and safety of DKF-MA102 in patients with prostate cancer.
Detailed description
This study is conducted to confirm the pharmacodynamic effects, efficacy, and safety of DKF-MA102 in prostate cancer patients by measuring the changes in serum testosterone levels.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DKF-MA102 | Administered twice at 12-week intervals |
Timeline
- Start date
- 2024-05-30
- Primary completion
- 2025-05-20
- Completion
- 2025-05-20
- First posted
- 2024-07-08
- Last updated
- 2024-07-08
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06490328. Inclusion in this directory is not an endorsement.